Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
KEYWORDS: dabigatran, warfarin, people, manufacturer, erg, treatment, daily, committee, twice daily, twice, stroke, inr, compared, years, dabigatran twice

to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final appraisal document. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has atrial fibrillation and the healthcare professional responsible for their care thinks that dabigatran etexilate is the right treatment, it should be available for use, in line with NICE's recommendations.
